Idasanutlin治疗真性红细胞增多症患者中TP53突变克隆的短暂扩增
该研究基于一项Idasanutlin治疗真性红细胞增多症(PV)的1期试验,通过测序发现5例患者携带12个TP53突变,其中部分突变在基线时已存在并在治疗中扩增;停药后8/9个突变VAF下降,随访19-32个月未观察到疾病进展。提示Idasanutlin可能促进TP53突变克隆的短暂扩增。
要点
- Idasanutlin治疗PV可伴随TP53突变亚克隆的扩增,但部分突变基线时已存在。
- 停药后多数TP53突变VAF下降,提示扩增为短暂性。
- 随访19-32个月未观察到进展为骨髓纤维化或MPN急变期。
核心结论
- Idasanutlin治疗可能促进PV患者TP53突变克隆的短暂扩增,但未观察到疾病进展。
研究设计与样本
- 基于一项Idasanutlin治疗PV的1期试验,对患者进行终点测序和基线样本原始测序数据分析。
主要发现
- 终点测序发现5例患者携带12个TP53突变,仅1例基线时已知携带TP53突变。
- 基线样本原始数据分析显示部分TP53突变在基线时已存在并在治疗中扩增。
- 5例中4例获得随访样本,停药后9个TP53突变中8个的VAF下降。
- 随访19-32个月,未观察到进展为骨髓纤维化或MPN急变期。
临床怎么用
- PV患者接受Idasanutlin治疗时需监测TP53突变克隆动态,但短暂扩增不一定代表临床进展。
局限性
- 需更大规模的高分辨率低VAF突变检测研究,以明确患者是否在Idasanutlin治疗后获得新发TP53突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activation of the P53 pathway through inhibition of MDM2 using nutlins has shown clinical promise in the treatment of solid tumors and hematologic malignancies. There is concern, however, that nutlin therapy might stimulate the emergence or expansion of TP53-mutated subclones. We recently published the results of a phase 1 trial of idasanutlin in patients with polycythemia vera (PV) that revealed tolerability and clinical activity. Here, we present data indicating that idasanutlin therapy is associated with expansion of TP53 mutant subclones. End-of-study sequencing of patients found that 5 patients in this trial harbored 12 TP53 mutations; however, only 1 patient had been previously identified as having a TP53 mutation at baseline. To identify the origin of these mutations, further analysis of raw sequencing data of baseline samples was performed and revealed that a subset of these mutations was present at baseline and expanded during treatment with idasanutlin. Follow-up samples were obtained from 4 of 5 patients in this cohort, and we observed that after cessation of idasanutlin, the variant allele frequency (VAF) of 8 of 9 TP53 mutations decreased. Furthermore, disease progression to myelofibrosis or myeloproliferative neoplasm blast phase was not observed in any of these patients after 19- to 32-month observation. These data suggest that idasanutlin treatment may promote transient TP53 mutant clonal expansion. A larger study geared toward high-resolution detection of low VAF mutations is required to explore whether patients acquire de novo TP53 mutations after idasanutlin therapy.
引用
- Marcellino BK, Farnoud N, Cassinat B, et al. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Adv. 2020. PMID: 33216890. doi:10.1182/bloodadvances.2020002379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。